Expert Highlights Next Steps to Evolve the Treatment Landscape of Urothelial Cancer
Peter Grivas, MD, PhD, discusses the next steps necessary for the treatment landscape of advanced urothelial cancer to evolve.
Peter Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor of oncology, University of Washington, Seattle Cancer Care Alliance, discusses the next steps necessary for the treatment landscape of advanced urothelial cancer to evolve.
Grivas says we need more effective therapies. Currently, only chemotherapy and immunotherapy agents are approved, but there are trials investigating the role of FGFR inhibitors and antibody-drug conjugates. The FDA has granted a breakthrough therapy designation to erdafitinib, an FGFR inhibitor, and the data has looked promising so far.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
